LG CNS, the IT services and digital transformation arm of LG Group, is deploying artificial intelligence solutions in the pharmaceutical and biotechnology sector through a government-supported AI drug research programme and automated quality assessment system for pharmaceutical products.

The initiative is part of the Ministry of Health and Welfare’s AI-driven drug R&D programme, which involves an investment of around 37.1 billion won (€22m) over four years and three months.

LG CNS is responsible for developing an AI platform to design and support clinical trials for new drugs and for creating a management framework that uses agentic AI to coordinate models developed by other institutions, generating system-wide efficiencies.

The platform uses federated learning, enabling hospitals and research centres to train AI models collaboratively without sharing sensitive data externally, protecting patient privacy while reducing the time required to move from preclinical to clinical stages.

Kim Tae-hoon, senior vice president of LG CNS’ AI cloud business, said the company’s “AI transformation capabilities in pharma and biotech are being recognized by both government and industry partners, leading to real business outcomes.” He added that LG CNS intends to become a “true game changer delivering differentiated customer value” for Korea’s pharmaceutical and biotech industry.

LG CNS has also implemented its agentic AI platform, AgenticWorks, to automate Chong Kun Dang’s annual product quality review (APQR). The solution deploys 30 AI agents that manage data collection, analysis, validation, and report generation, cutting reporting time by over 90 percent and freeing staff to focus on final validation and quality improvement.

By combining AI for drug development with automated quality processes, LG CNS is establishing a measurable impact on efficiency, compliance, and innovation in the pharmaceutical and biotech sectors.

Read the full article on LG CNS’ AI initiatives in pharma and biotech.